This Drug Reduces Symptoms Before a Migraine Strikes, Study Shows
That's the conclusion reached after a large clinical trial tested hundreds of migraine patients taking the medication at the onset of prodrome symptoms.
The result suggests that ubrogepant might be effective for treating the entire migraine as it evolves, rather than just the head pain – and narrows down the mechanisms behind the condition.
Migraine is a neurological affliction that affects an estimated 14 to 15 percent of the global population, yet it remains poorly understood, and difficult to treat effectively. It's known for its searing, debilitating head pain, but the anatomy of a migraine is much more complex and longer-lasting than just the head pain.
Broadly, a migraine consists of three to four stages: the prodrome, during which the patient experiences symptoms such as light sensitivity, nausea, neck pain, and brain fog; aura, characterized by vision disturbances, including blind spots and flashing lights; the headache attack itself; and the postdrome, characterized by brain fog and fatigue.
Put together, this sequence of events can last up to more than a week. It's quite unpleasant.
Most treatments focus on the headache portion, since it's the most debilitating. Even studies on treatments designed to be taken during the prodrome phase have concentrated on blocking the headache, rather than treating the prodrome itself.
Led by neurologist Peter Goadsby of Kings College London, a team of researchers has now conducted a trial on whether or not ubrogepant, a migtainte treatment available in the US under the brand name Ubrelvy, also works on the prodrome.
Scientists want to know not just how to treat the entirety of a migraine – although that's a desired goal – but to help determine what drives a migraine attack.
"It has long been argued whether migraine is primarily a disease of the brain or of peripheral, specifically vascular, origin," the researchers write in their paper. "The new data firmly support a brain origin for migraine attacks."
Ubrogepant is a drug that does not prevent migraine attacks, but reduces the severity of the pain associated with an attack. It belongs to a class of drugs called calcitonin gene-related peptide (CGRP) receptor antagonists. Ubrogepant, and other drugs belonging to the same class, block the action of CGRP, a peptide associated with migraine.
Goadsby and his colleagues recruited hundreds of migraine patients for a double-blind study. The 438 study participants, aged between 18 and 75, and all with at least a one-year history of migraine, were put in groups.
One group was given ubrogepant at the onset of prodrome symptoms; the other was given a placebo. Then, during a second event at least seven days later, the groups switched. The patients initially given the drug were given the placebo, and vice versa. Neither the researchers nor the participants knew which group was receiving which.
After taking the drug or the placebo, the participants were tasked with reporting changes in their symptoms, which included photo- and phonophobia, dizziness, fatigue, neck pain or stiffness, and brain fog. The patients taking the drug experienced a significantly higher reduction in their symptoms than the patients taking the placebo.
One hour after taking ubrogepant, patients reported brain fog easing. After two hours, photophobia, or sensitivity to light, decreased. After three hours, neck problems eased. Between four and 24 hours after taking the drug, phonophobia (sensitivity to sound) and dizziness lessened, too.
These results suggest that CGRP receptor antagonists might be effective at treating prodromal migraine symptoms, the researchers say.
"As premonitory symptoms can be disabling, their treatment alone is clinically relevant, beyond the consideration that treatment during the prodrome prevents headache onset and improves function over 24 to 48 hours, as demonstrated in the primary analysis of the study," the researchers write.
In addition: "Broadly, the findings of the clinical trial support imaging studies that have identified central nervous system sites as the locus of initiation of a migraine attack."
There are several routes forward from here. The study didn't look at the effects of ubrogepant on the aura and postdrome phases of migraine, which could warrant further investigation.
Future work could also probe further to try and narrow down the cause of migraine, and determine whether CGRP receptor antagonists might offer relief for the entire course of a migraine event.
The research has been published in Nature Medicine.
Shingles Vaccine Can Reduce Risk of Stroke And Heart Attack, Study Finds
Spikes of Bird Flu in Cats Could Be a Warning of a Future Pandemic
HIV Drugs Dramatically Lower Risk of Alzheimer's Disease, Study Finds
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
3 days ago
- Forbes
The Perseids Are Peaking Now — Here's How To Beat The Moonlight
When is the Perseid meteor shower? Happening right now — and peaking this week — the fastest and brightest meteor shower of the year will likely underwhelm. 'The Perseid meteor shower is active between Jul. 17 and Aug. 24,' said Dr Shyam Balaji, theoretical physicist at King's College London, in an email. 'It peaks on Aug. 12, but the light from the full moon might make meteors harder to spot that night.' Harder, but not impossible. Here's everything you need to know about — and how and when to get the best view of — the Perseid meteor shower this week. Peak Night Is August 12–13 — But Moonlight Will Be a Factor On the peak night, Aug. 12–13, a bright gibbous moon — about 84% lit and rising just as it starts to get dark — will vastly reduce the visibility of 'shooting stars.' 'The light from the full moon might make meteors harder to spot that night,' said Balaji. The best chance may be just after sunset and before moonrise, when the sky is still dark, on Aug. 12 — but it's a narrow window. Expect About 5-10 'Shooting Stars' Per Hour On The Peak Night Although the Perseids can see about 75 'shooting stars' per hour during their peak night, this year observers might spot only five to 10 meteors per hour. That's the huge impact of a bright gibbous moon. 'The Perseid meteor shower is caused by the Earth travelling through the debris left by a comet called Swift-Tuttle,' said Balaji. 'The debris falls through the Earth's atmosphere, and as it burns up, you get the meteor shower display.' Find An Open Space With A Clear View Although strong moonlight means there's no point in escaping to dark skies for the Perseids this year, you still need to think about your observing location. "The key would be to find an open space with a clear view of as much of the sky as possible, since meteors can appear anywhere,' said Dr. Qicheng Zhang, astronomer at Lowell Observatory in Flagstaff, Arizona, in an email. He adds that smoke and smog can also make a noticeable difference. The Peak Night Is Still Worth Watching Despite the Moon Although the Perseid meteor shower will be marred by moonlight, it can still be an astronomical highlight for stargazers. That's because some of the brighter 'shooting stars' — called fireballs — will still be visible to those with lots of patience. The best chance may be just after sunset and before moonrise, when the sky is still dark, on Aug. 12 — but it's a narrow window. There may be reasons to look for Perseids in a darker sky, but there's still likely to be a visible uptick in rates around the peak night. 'The Perseids in the middle of the month are still likely to produce the most visible meteors despite the moon,' said Zhang. You Can Take Evasive Action To Beat The Strong Moonlight There's not much you can do about moonlight interrupting the peak of the Perseid meteor shower, but you can lessen its impact by keeping the moon behind you and, better still, watching from somewhere in shadow. However, be careful that the obstruction you use to block the moon doesn't also block too much of the night sky. That's likely to be a bigger problem the higher the moon rises into the sky after midnight. The Nights Following The Peak Are Also Worth Being Outside For The nights immediately afterwards are also worth being outside for looking for 'shooting stars.' 'The moon rises slightly later each night around the time of the Perseids peak, giving a slightly longer moonless window for later nights,' said Zhang. 'However, typically, the meteor rate drops off substantially from the peak — one would probably still see more meteors on the peak night than afterward, all else equal.' There Could Be A Sudden Outburst Sudden, unpredictable outbursts could increase that number, but they're rare and difficult to forecast. 'Outbursts are notoriously hard to predict since they require us to know precisely how the parent comet responsible for the meteors was behaving centuries ago, long before astronomers were observing it in any detail,' said Zhang. 'Strong outbursts in meteor activity may last only a few hours, and because they're unpredictable in time, require either a lot of luck or watching for many hours to have a reasonable chance of catching.' The Perseid meteor shower is caused by the Earth travelling through the debris left by comet Swift-Tuttle. Look To The North-East For The Best Chance 'Shooting stars' can appear anywhere in the night sky at any time. However, there is a radiant point, a specific location in the night sky from which the meteors appear to originate. 'The best place to view the Perseid meteor shower is in the Northeast near the constellation Perseus,' said Balaji. 'While you can look at the whole sky and are likely to see a meteor, that's the target location.' The brightly lit moon might upset your view of the Perseid meteor shower in 2025, but it will simultaneously create a rather beautiful sight. Look alongside the moon as it rises in the east — albeit uncomfortably near the Perseids' radiant point — and you'll see the planet Saturn, close to looking its biggest, brightest and best in 2025. Wishing you clear skies and wide eyes.
Fox News
6 days ago
- Fox News
Coffee vs. matcha: Is your morning brew helping or hurting your health?
Tim Spector, a King's College London professor of epidemiology and a leading microbiome researcher, dives into the science, benefits and tradition behind matcha.
Medscape
05-08-2025
- Medscape
Ketamine's Antidepressant Action May Depend on Opioid System
Activation of the body's opioid system may be required for ketamine's antidepressant effects, new research hinted. In a small study of adults with major depressive disorder, taking the opioid blocker naltrexone before a low-dose ketamine infusion both blunted the surge in glutamate — a key brain chemical linked to mood — and reduced ketamine's rapid antidepressant benefit the next day. 'These results suggest that opioid receptors help mediate ketamine's effects and that blocking opioid receptors may lessen ketamine's acute mood-lifting action,' lead researcher Luke Jelen, MBBS, clinical lecturer in psychiatry, King's College London, London, England, told Medscape Medical News . 'However, this was a small, mechanistic study, not a treatment trial, so there is no immediate indication to change clinical practice or avoid naltrexone. Larger, dedicated clinical studies are required before recommending any alteration to current protocols,' Jelen cautioned. The study was published online on July 24 in Nature Medicine . New Mechanistic Insights Ketamine's rapid-acting antidepressant effects are thought to work by transiently elevating glutamate in the anterior cingulate cortex and other frontal regions, setting off a cascade of plasticity-related pathways. Prior animal and small human studies have suggested that activating mu-opioid receptors might be necessary for ketamine's mood benefits. To investigate, Jelen and colleagues enrolled 26 adults with moderate-to-severe depression in a randomized double-blind crossover trial separated by 3 weeks. Participants received either oral placebo or 50 mg naltrexone 1 hour before receiving intravenous ketamine (0.5 mg/kg). During the first 30 minutes of each infusion, they measured brain glutamatergic activity in the anterior cingulate cortex using functional magnetic resonance spectroscopy. Depressive symptoms were measured before and 24 hours after infusion, when ketamine's antidepressant effects peak, using the Montgomery-Åsberg Depression Rating Scale (MADRS). Compared with placebo, pretreatment with a single 50-mg dose of oral naltrexone reduced the brain's glutamatergic response and dampened the average improvement on MADRS measured 24 hours later, the researchers observed. Specifically, the glutamate signal climbed significantly during ketamine when participants had taken placebo, but the rise was significantly smaller when they had taken naltrexone ( P = .029; Cohen's d = 0.34). 'We also identified a sex-related effect: The attenuating effect of naltrexone on glutamate activity appeared more pronounced in males with depression than in females with depression,' Jelen said. Alongside the attenuation of ketamine-induced glutamatergic activity, naltrexone pretreatment also led to less marked reductions in clinician-rated MADRS scores 24 hours after infusion — equating to a 28% attenuation in the main effect of ketamine ( P = .023), the researchers reported. Reductions in self-reported depressive measures were numerically lower in the presence of naltrexone than in the presence of placebo, but the differences were not statistically significant. 'The possibility of an opioid mechanism underlying the antidepressant mechanisms of ketamine has been a recent subject of considerable debate. Our study provides evidence that opioid system activation may contribute to the acute antidepressant effects of ketamine,' the authors wrote. Looking ahead, Jelen told Medscape Medical News , a larger, well-powered study should include a true placebo-infusion arm to disentangle naltrexone's effects on both ketamine and placebo responses. He also noted that adding PET imaging would directly quantify opioid-receptor engagement, and prespecified analyses by sex are essential, given the stronger glutamate-dampening effect observed in men. 'Understanding more about how ketamine works can lead to treatment being personalized for different people, which is vital for creating safe and effective treatments,' Jelen said.
